Sharh maqola

Human CD56bright NK Cells: An Update

Tatiana MichelDepartment of Infection and Immunity, Luxembourg Institute of Health , L-4354 Esch-sur-Alzette ,Aurélie PoliDepartment of Infection and Immunity, Luxembourg Institute of Health , L-4354 Esch-sur-Alzette ,Angélica CuapioDepartment of Vascular Biology and Thrombosis Research, Medical University of Vienna , A-1090 Vienna ,Benjamin BriquemontDepartment of Infection and Immunity, Luxembourg Institute of Health , L-4354 Esch-sur-Alzette ,Gilles IserentantDepartment of Infection and Immunity, Luxembourg Institute of Health , L-4354 Esch-sur-Alzette ,Markus OllertAllergy Center, Department of Dermatology Odense Research Centre for Anaphylaxis, University of Southern Denmark , DK-5000 Odense ,Jacques ZimmerDepartment of Infection and Immunity, Luxembourg Institute of Health , L-4354 Esch-sur-Alzette ,

2016en

ABI

Annotatsiya

Human NK cells can be subdivided into various subsets based on the relative expression of CD16 and CD56. In particular, CD56(bright)CD16(-/dim) NK cells are the focus of interest. They are considered efficient cytokine producers endowed with immunoregulatory properties, but they can also become cytotoxic upon appropriate activation. These cells were shown to play a role in different disease states, such as cancer, autoimmunity, neuroinflammation, and infection. Although their phenotype and functional properties are well known and have been extensively studied, their lineage relationship with other NK cell subsets is not fully defined, nor is their precise hematopoietic origin. In this article, we summarize recent studies about CD56(bright) NK cells in health and disease and briefly discuss the current controversies surrounding them.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.4049/jimmunol.1502570

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar